Asia-Pacific’s medical devices industry saw a drop of 48.89% in deal activity during October 2022, when compared with the last 12-month average, led by Chende Capital, SoftBank Vision Fund 2, Yiheng Capital Partners, Yuanyi Capital and Zhongwei Capital HoldingLimited’s $100m venture financing of stake in Xunshi Technology, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 23 medical devices industry deals worth $189.1m were announced for the region in October 2022, against the 12-month average of 45 deals.
Of all the deal types, venture financing saw most activity in October 2022 with 21 transactions, representing a 91.3% share for the region.
In second place was M&A with two deals capturing an 8.7% share of the overall deal activity for the month.
In terms of value of deals, venture financing was the leading category in Asia-Pacific’s medical devices industry with $177.36m, followed by M&A deals totalled $11.7m.
Asia-Pacific medical devices industry deals in October 2022: Top deals
The top five medical devices deals accounted for 82.8% of the overall value during October 2022.
The combined value of the top five medical devices deals stood at $156.49m, against the overall value of $189.1m recorded for the month.
The top five medical devices industry deals of October 2022 tracked by GlobalData were:
1) Chende Capital, SoftBank Vision Fund 2, Yiheng Capital Partners, Yuanyi Capital and Zhongwei Capital HoldingLimited’s $100m venture financing deal with Xunshi Technology
2) The $15m venture financing of Shenzhen Jinbaihui Biological by Bank of China Guangdong Finance
3) Longping Biosciences, Qianhai Great Wall Fund Management (Shenzhen) and Qiluo Investment’s $13.89m venture financing deal with Shenzhen Sailu Medical Technology
4) The $13.8m venture financing of Hangzhou Shenluo Medical Technology by Boyuan Capital and SDIC Chuanghe Fund Management
5) Changan Huitong, October Capital, Season Ventures and Yinglian Health Fund’s $13.8m venture financing deal with Zhejiang Pushkang Biotechnology